1. Volume 84, Issue 4, Pages 786-794 (October 2013)
Distinct injury markers for the early detection and prognosis of incident acute kidney injury in critically ill adults with preserved kidney function 
Edward D. Siew, Lorraine B. Ware, Aihua Bian, Ayumi Shintani, Svetlana K. Eden, Nancy Wickersham, Ben Cripps, T. Alp Ikizler 
Kidney International 
Volume 84, Issue 4, Pages (October 2013)
DOI: /ki
Copyright © 2013 International Society of Nephrology Terms and Conditions

2. Figure 1
Study scheme. AKI, acute kidney injury; ICU, intensive care unit.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

3. Figure 2
Box-plot of changes in serum creatinine between acute kidney injury (AKI) cases and non-AKI controls. The first, second, and third panels represent the baseline serum creatinine, the highest serum creatinine within 24h after biomarker measurement, and the highest serum creatinine within 24–48h of biomarker measurement, respectively. Creatinine measurements were ordered by point-of-care personnel. P-values <0.05 denote statistical significance.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

4. Figure 3
Box-plot of levels of urine cystatin C (uCysC) urine neutrophil gelatinase–associated lipocalin (uNGAL) and L-type fatty acid–binding protein (L-FABP) grouped by acute kidney injury (AKI) versus non-AKI status. Levels are adjusted for urine creatinine values. P-values < denote statistical significance.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

5. Figure 4
Discrimination of AKI versus non-AKI status within 48 hours of urine neutrophil gelatinase–associated lipocalin (uNGAL) and uL-FABP measurement. (a) Area under the receiver-operating curves for uNGAL, L-type fatty acid–binding protein (L-FABP), and both biomarkers combined for discriminating any future acute kidney injury (AKI) from non-AKI status. (b) Area under the receiver-operating curves for urine NGAL, L-FABP, and both biomarkers combined for discriminating future AKIN stages II and III from non-AKI status. AUC, area under the curve.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

6. Figure 5
Box-plots of levels of urine neutrophil gelatinase–associated lipocalin (uNGAL) and L-type fatty acid–binding protein (L-FABP) grouped according to whether patients experienced the composite outcome of dialysis or mortality.P-values < denote statistical significance.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions